HLA/KIR restraint of HIV: Surviving the fittest

Annual Review of Immunology

Volumn 29, Issue , 2011, Pages 295-317

  Bashirova, Arman A ^a,b   Thomas, Rasmi ^a,b   Carrington, Mary ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

CTL; escape mutations; GWAS; host genetics; NK cells; viral evolution

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; GENE LOCUS; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS IMMUNITY;

ANIMALS; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMANS; RECEPTORS, KIR; T-LYMPHOCYTES;

EID: 79953053034     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-031210-101332     Document Type: Article

References (156)

1. Shiina T, Hosomichi K, Inoko H, Kulski JK. 2009. TheHLA genomic loci map: expression, interaction, diversity and disease. J. Hum. Genet. 54:15-39.
2. Marsh SGE, Parham P, Barber LD. 2000. The HLA FactsBook. San Diego: Academic. 398 pp.
3. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, et al. 2001. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344:1668-75. (Pubitemid 32479964)
4. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. 2008. Functions of natural killer cells. Nat. Immunol. 9:503-10. (Pubitemid 351560519)
5. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, et al. 2000. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc. Natl. Acad. Sci. USA 97:4778-83. (Pubitemid 30238634)
6. Middleton D, Gonzelez F. 2010. The extensive polymorphism of KIR genes. Immunology 129:8-19.
7. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, et al. 1997. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7:739-51. (Pubitemid 28064888)
8. Carrington M, MartinMP, van Bergen J. 2008. KIR-HLA intercourse in HIV disease. Trends Microbiol. 16:620-27.
9. Carr WH, Pando MJ, Parham P. 2005. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J. Immunol. 175:5222-29. (Pubitemid 41456407)
10. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, et al. 2001. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J. Immunol. 166:2992-3001. (Pubitemid 33117294)
11. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. 2006. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J. Exp. Med. 203:633-45.
12. Thomas R, Yamada E, Alter G, Martin MP, Bashirova AA, et al. 2008. Novel KIR3DL1 alleles and their expression levels onNK cells: convergent evolution of KIR3DL1 phenotype variation? J. Immunol. 180:6743-50.
13. Jonsson AH, Yokoyama WM. 2009. Natural killer cell tolerance licensing and other mechanisms. Adv. Immunol. 101:27-79.
14. Desrosiers MP, Kielczewska A, Loredo-Osti JC, Adam SG, Makrigiannis AP, et al. 2005. Epistasis between mouse Klra andmajor histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat. Genet. 37:593-99. (Pubitemid 40774887)
15. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-79. (Pubitemid 37070272)
16. Brenchley JM, Douek DC. 2008. The mucosal barrier and immune activation in HIV pathogenesis. Curr. Opin. HIV AIDS 3:356-61. (Pubitemid 351521021)
17. Deeks SG, Walker BD. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-16. (Pubitemid 47418678)
18. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-70. (Pubitemid 26001148)
19. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, et al. 2006. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296:1498-506. (Pubitemid 44465514)
20. Langlade-Demoyen P, Michel F, Hoffenbach A, Vilmer E, Dadaglio G, et al. 1988. Immune recognition of AIDS virus antigens by human and murine cytotoxic T lymphocytes. J. Immunol. 141:1949-57.
21. Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, et al. 1987. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:345-48. (Pubitemid 17097655)
22. Walker BD, Flexner C, Paradis TJ, Fuller TC, Hirsch MS, et al. 1988. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 240:64-66.
23. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. 1994. Virus-specific CD8+ cytotoxic Tlymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-10. (Pubitemid 24258634)
24. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-55. (Pubitemid 24183063)
25. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. 1999. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991-98. (Pubitemid 29149355)
26. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-60.
27. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. 2004. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10:282-89. (Pubitemid 38667619)
28. Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, et al. 2007. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J. Virol. 81:12608-18. (Pubitemid 350085874)
29. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, et al. 2006. Fitness cost of escapemutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80:3617-23.
30. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, et al. 2009. HLA-B57/B-5801 human immunodeficiency virus type 1 elite controllers select for rare Gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. J. Virol. 83:2743-55.
31. Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, et al. 2007. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 315:1583-86. (Pubitemid 46449476)
32. MooreCB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296:1439-43. (Pubitemid 34553083)
33. Brumme ZL, Brumme CJ, Heckerman D, Korber BT, Daniels M, et al. 2007. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog. 3:e94.
34. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, et al. 2005. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79:13239-49. (Pubitemid 41508139)
35. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, et al. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205-11. (Pubitemid 27064706)
36. Brumme ZL, Brumme CJ, Carlson J, Streeck H, John M, et al. 2008. Marked epitope-and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J. Virol. 82:9216-27.
37. Cao J, McNevin J, Malhotra U, McElrath MJ. 2003. Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J. Immunol. 171:3837-46. (Pubitemid 37254590)
38. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, et al. 2007. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B-5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J. Virol. 81:8346-51. (Pubitemid 47101520)
39. Jones NA, Wei X, Flower DR, Wong M, Michor F, et al. 2004. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J. Exp. Med. 200:1243-56. (Pubitemid 39552566)
40. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, et al. 2001. Clustered mutations in HIV-1 gag are consistently required for escape fromHLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193:375-86.
41. Liu Y, McNevin J, Cao J, Zhao H, Genowati I, et al. 2006. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J. Virol. 80:9519-29. (Pubitemid 44435628)
42. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, et al. 1997. Positive selection ofHIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94:1890-95. (Pubitemid 27113932)
43. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, et al. 2009. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253-72.
44. Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, et al. 2004. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escapemutation in human immunodeficiency virus type 1 infection. J. Virol. 78:7069-78. (Pubitemid 38781545)
45. Draenert R, Allen TM, Liu Y, Wrin T, Chappey C, et al. 2006. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J. Exp. Med. 203:529-39.
46. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, et al. 2009. Evolution of HLA-B-5703 HIV-1 escape mutations in HLA-B-5703-positive individuals and their transmission recipients. J. Exp. Med. 206:909-21.
47. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, et al. 2009. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458:641-45.
48. Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, et al. 2008.HLAclass I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J. Virol. 82:6434-46. (Pubitemid 351875121)
49. Turnbull EL, Wong M, Wang S, Wei X, Jones NA, et al. 2009. Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. J. Immunol. 182:7131-45.
50. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, et al. 2009. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J. Virol. 83:7641-48.
51. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, et al. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77:2081-92. (Pubitemid 36110021)
52. Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, et al. 2004. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J. Virol. 78:3233-43. (Pubitemid 38568263)
53. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. 2002. Magnitude of functional CD8+ T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J. Virol. 76:2298-305. (Pubitemid 34150698)
54. Julg B, Williams KL, Reddy S, Bishop K, Qi Y, et al. 2010. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J. Virol. 84:5540-49.
55. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53. (Pubitemid 46067385)
56. Ramduth D, Chetty P, MngquandanisoNC, Nene N, Harlow JD, et al. 2005. Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8+ and CD4+ cell responses. J. Infect. Dis. 192:1588-96. (Pubitemid 41504694)
57. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, et al. 2007. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178:2746-54. (Pubitemid 46333151)
58. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-89. (Pubitemid 43882629)
59. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, et al. 2008. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82:5398-407. (Pubitemid 351705247)
60. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, et al. 2010. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 6:e1000917.
61. Horton H, Frank I, Baydo R, Jalbert E, Penn J, et al. 2006. Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J. Immunol. 177:7406-15. (Pubitemid 44715111)
62. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, et al. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3:1061-68. (Pubitemid 35363659)
63. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, et al. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. USA 104:6776-81. (Pubitemid 47175577)
64. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. 2003. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852-56. (Pubitemid 36254145)
65. Shedlock DJ, Shen H. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337-39. (Pubitemid 36433726)
66. Sun JC, Williams MA, Bevan MJ. 2004. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol. 5:927-33. (Pubitemid 39276237)
67. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. 2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417:95-98. (Pubitemid 34498823)
68. McNeil AC, Shupert WL, Iyasere CA, Hallahan CW, Mican JA, et al. 2001. High-level HIV-1 viremia suppresses viral antigen-specific CD4+ T cell proliferation. Proc. Natl. Acad. Sci. USA 98:13878-83. (Pubitemid 33115992)
69. Palmer BE, Boritz E, Blyveis N, Wilson CC. 2002. Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4+ T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. J. Virol. 76:5925-36. (Pubitemid 34556287)
70. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, et al. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-50. (Pubitemid 27509814)
71. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. 2002. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ andCD28+IL-2+ CD4Tcell responses is associated with nonprogression in HIV-1 infection. J. Immunol. 169:6376-85. (Pubitemid 36903486)
72. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, et al. 2002. Characterization of CD4+ CTLs ex vivo. J. Immunol. 168:5954-58.
73. Norris PJ, Moffett HF, Yang OO, Kaufmann DE, Clark MJ, et al. 2004. Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4+ T cells. J. Virol. 78:8844-51. (Pubitemid 39025149)
74. Sacha JB, Giraldo-Vela JP, Buechler MB, Martins MA, Maness NJ, et al. 2009. Gag-and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc. Natl. Acad. Sci. USA 106:9791-96.
75. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys frommucosal simian immunodeficiency virus challenge. Nat. Med. 15:293-99.
76. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-20.
77. McMichael AJ, Kelleher A. 1999. The arrival of HLA class II tetramers. J. Clin. Investig. 104:1669-70.
78. Kaufmann DE, Bailey PM, Sidney J, Wagner B, Norris PJ, et al. 2004. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 78:4463-77. (Pubitemid 38501066)
79. Malhotra U, Holte S, Dutta S, Berrey MM, Delpit E, et al. 2001. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J. Clin. Investig. 107:505-17. (Pubitemid 32167997)
80. Ramduth D, Day CL, Thobakgale CF, Mkhwanazi NP, de Pierres C, et al. 2009. Immunodominant HIV-1 CD4+ T cell epitopes in chronic untreated clade C HIV-1 infection. PLoS ONE 4:e5013.
81. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. 1996. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2:338-42. (Pubitemid 26080655)
82. CohenGB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, et al. 1999. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protectsHIV-infected cells fromNKcells. Immunity 10:661-71. (Pubitemid 29302919)
83. Alter G, Teigen N, Ahern R, Streeck H, Meier A, et al. 2007. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J. Infect. Dis. 195:1452-60. (Pubitemid 46717463)
84. Alter G, Rihn S, Walter K, Nolting A, Martin M, et al. 2009. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J. Virol. 83:6798-805.
85. Bonaparte MI, Barker E. 2003. Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes. AIDS 17:487-94. (Pubitemid 36293101)
86. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, et al. 2003. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. USA 100:15011-16. (Pubitemid 37518008)
87. Ullum H, Gotzsche PC, Victor J, Dickmeiss E, Skinhoj P, Pedersen BK. 1995. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. J. Exp. Med. 182:789-99.
88. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, et al. 2005. Characterization ofCD56?/CD16+ natural killer (NK) cells: a highly dysfunctionalNKsubset expanded in HIV-infected viremic individuals. Proc. Natl. Acad. Sci. USA 102:2886-91. (Pubitemid 40299886)
89. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, et al. 2005. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 106:3366-69. (Pubitemid 41609166)
90. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, et al. 2008. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS ONE 3:e3907.
91. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, et al. 2009. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 5:e1000791.
92. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. 2007. A whole-genome association study of major determinants for host control of HIV-1. Science 317:944-47. (Pubitemid 47301321)
93. Pelak K, Goldstein DB, Walley NM, Fellay J, Ge D, et al. 2010. Host determinants of HIV-1 control in African Americans. J. Infect. Dis. 201:1141-49.
94. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, et al. 2009. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J. Infect. Dis. 199:419-26.
95. Satta Y, O'HUigin C, Takahata N, Klein J. 1993. The synonymous substitution rate of the major histocompatibility complex loci in primates. Proc. Natl. Acad. Sci. USA 90:7480-84. (Pubitemid 23249973)
96. Klein J, O'Huigin C. 1994. MHC polymorphism and parasites. Philos. Trans. R. Soc. Lond. B Biol. Sci. 346:351-57;discussion 7-8.
97. Borghans JA, Beltman JB, De Boer RJ. 2004. MHC polymorphism under host-pathogen coevolution. Immunogenetics 55:732-39. (Pubitemid 38316678)
98. Carrington M, NelsonGW, Martin MP, Kissner T, Vlahov D, et al. 1999.HLAand HIV-1: heterozygote advantage and B-35-Cw-04 disadvantage. Science 283:1748-52.
99. Tang J, Costello C, Keet IP, Rivers C, Leblanc S, et al. 1999. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retrovir. 15:317-24. (Pubitemid 29115924)
100. O'Connor SL, Lhost JJ, Becker EA, Detmer AM, Johnson RC, et al. 2010. MHC heterozygote advantage in simian immunodeficiency virus-infected Mauritian cynomolgus macaques. Sci. Transl. Med. 2:22ra18.
101. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, et al. 2003. Advantage of rare HLA supertype in HIV disease progression. Nat. Med. 9:928-35. (Pubitemid 36889937)
102. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, et al. 2010. Nomenclature for factors of the HLA system, 2010. Tissue Antigens 75:291-455.
103. Martin MP, Carrington M. 2005. Immunogenetics of viral infections. Curr. Opin. Immunol. 17:510-16. (Pubitemid 41207955)
104. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769-75.
105. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al. 2000. HLA B-5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 97:2709-14. (Pubitemid 30159236)
106. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, et al. 2005. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat. Med. 11:1290-92. (Pubitemid 41752907)
107. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, et al. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:405-11. (Pubitemid 26193012)
108. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197:563-71. (Pubitemid 351321534)
109. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, et al. 2003. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17:2581-91. (Pubitemid 38402336)
110. Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, et al. 2003. The differential ability of HLA B-5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J. Virol. 77:6889-98. (Pubitemid 36666882)
111. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, et al. 2006. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8+ T cell response against HIV-1. PLoS Med. 3:e403.
112. Kosmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, et al. 2010. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465:350-54.
113. Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S, et al. 1999. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol. 162:6942-46. (Pubitemid 29309424)
114. Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, et al. 1999. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodefi-ciency virus-1-infected individuals. Blood 93:936-41. (Pubitemid 29067859)
115. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212-17. (Pubitemid 27064707)
116. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, et al. 2007. Escape from the dominant HLAB27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 81:12382-93. (Pubitemid 350085852)
117. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, et al. 2004. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J. Virol. 78:8927-30. (Pubitemid 39025159)
118. Schneidewind A, Brumme ZL, Brumme CJ, Power KA, Reyor LL, et al. 2009. Transmission and longterm stability of compensated CD8 escape mutations. J. Virol. 83:3993-97.
119. Loffredo JT, Sidney J, Bean AT, Beal DR, Bardet W, et al. 2009. TwoMHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B-08 and HLA-B-2705, bind peptides with sequence similarity. J. Immunol. 182:7763-75.
120. Itescu S, Mathur-Wagh U, Skovron ML, Brancato LJ, Marmor M, et al. 1992. HLA-B35 is associated with accelerated progression to AIDS. J. Acquir. Immune Defic. Syndr. 5:37-45.
121. Sahmoud T, Laurian Y, Gazengel C, Sultan Y, Gautreau C, Costagliola D. 1993. Progression to AIDS in French haemophiliacs: association with HLA-B35. AIDS 7:497-500. (Pubitemid 23160961)
122. Scorza Smeraldi R, Fabio G, Lazzarin A, Eisera NB, Moroni M, Zanussi C. 1986. HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection. Lancet 2:1187-89. (Pubitemid 17204889)
123. Streeck H, Lichterfeld M, Alter G, Meier A, Teigen N, et al. 2007. Recognition of a defined region within p24 Gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J. Virol. 81:7725-31. (Pubitemid 47047858)
124. Steinle A, Falk K, Rotzschke O, Gnau V, Stevanovic S, et al. 1996. Motif ofHLA-B-3503 peptide ligands. Immunogenetics 43:105-7.
125. Smith KJ, Reid SW, Stuart DI, McMichael AJ, Jones EY, Bell JI. 1996. An altered position of the alpha 2 helix of MHC class I is revealed by the crystal structure of HLA-B-3501. Immunity 4:203-13.
126. Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, et al. 1992. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360:434-39.
127. Huang J, Goedert JJ, Sundberg EJ, Cung TD, Burke PS, et al. 2009. HLA-B-35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. J. Exp. Med. 206:2959-66.
128. Jin X, Gao X, Ramanathan M Jr, Deschenes GR, Nelson GW, et al. 2002. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B-35 genotypes. J. Virol. 76:12603-10. (Pubitemid 35386945)
129. Snary D, Barnstable CJ, Bodmer WF, Crumpton MJ. 1977. Molecular structure of human histocompatibility antigens: the HLA-C series. Eur J. Immunol. 7:580-85. (Pubitemid 8172837)
130. Bashirova AA, Martin MP, McVicarDW, CarringtonM. 2006. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu. Rev. Genomics Hum. Genet. 7:277-300. (Pubitemid 44627931)
131. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, et al. 2004. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:872-74. (Pubitemid 39038423)
132. Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, et al. 2005. Genome-wide associations of gene expression variation in humans. PLoS Genet. 1:e78.
133. Thomas R, Apps R, Qi Y, Gao X, Male V, et al. 2009. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat. Genet. 41:1290-94.
134. Specht A, Telenti A, Martinez R, Fellay J, Bailes E, et al. 2010. Counteraction of HLA-C-mediated immune control of HIV-1 by Nef. J. Virol. 84:7300-11.
135. Makadzange AT, Gillespie G, Dong T, Kiama P, Bwayo J, et al. 2010.
136. Lacap PA, Huntington JD, Luo M, Nagelkerke NJ, Bielawny T, et al. 2008. Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. AIDS 22:1029-38. (Pubitemid 351769741)
137. Ndung'u T, Gaseitsiwe S, Sepako E, Doualla-Bell F, Peter T, et al. 2005. Major histocompatibility complex class II (HLA-DRB and -DQB) allele frequencies in Botswana: association with human immunodeficiency virus type 1 infection. Clin. Diagn. Lab. Immunol. 12:1020-28. (Pubitemid 41324531)
138. Tang J, Penman-Aguilar A, Lobashevsky E, Allen S, Kaslow RA. 2004. HLA-DRB1 and -DQB1 alleles and haplotypes in Zambian couples and their associations with heterosexual transmission of HIV type 1. J. Infect. Dis. 189:1696-704. (Pubitemid 38648300)
139. Giraldo-Vela JP, Rudersdorf R, Chung C, Qi Y, Wallace LT, et al. 2008. The major histocompatibility complex class II alleles Mamu-DRB1-1003 and -DRB1?0306 are enriched in a cohort of simian immunodeficiency virus-infected rhesus macaque elite controllers. J. Virol. 82:859-70.
140. Kulkarni S, Martin MP, Carrington M. 2008. The Yin and Yang of HLA and KIR in human disease. Semin. Immunol. 20:343-52.
141. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, et al. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31:429-34. (Pubitemid 35154456)
142. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, et al. 2007. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39:733-40. (Pubitemid 46848586)
143. Qi Y, Martin MP, Gao X, Jacobson L, Goedert JJ, et al. 2006. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2:e79.
144. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, et al. 2007. Differential natural killer cellmediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp.Med. 204:3027-36. (Pubitemid 350179568)
145. Barbour JD, Sriram U, Caillier SJ, Levy JA, Hecht FM, Oksenberg JR. 2007. Synergy or independence? Deciphering the interaction of HLA class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog. 3:e43.
146. Gaudieri S, DeSantis D, McKinnon E, Moore C, Nolan D, et al. 2005. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun. 6:683-90. (Pubitemid 41741713)
147. Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, Lanier LL. 2007. Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J. Immunol. 178:647-51. (Pubitemid 46095135)
148. O'ConnorGM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. 2007. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J. Immunol. 178:235-41. (Pubitemid 46033606)
149. Norman PJ, Abi-Rached L, Gendzekhadze K, Korbel D, Gleimer M, et al. 2007. Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat. Genet. 39:1092-99. (Pubitemid 47340657)
150. Single RM, Martin MP, Gao X, Meyer D, Yeager M, et al. 2007. Global diversity and evidence for coevolution of KIR and HLA. Nat. Genet. 39:1114-19. (Pubitemid 47342436)
151. Hollenbach JA, Meenagh A, Sleator C, Alaez C, Bengoche M, et al. 2010. Report from the killer immunoglobulin-like receptor (KIR) anthropology component of the 15th International Histocompatibility Workshop: worldwide variation in the KIR loci and further evidence for the co-evolution of KIR and HLA. Tissue Antigens 76:9-17.
152. Boulet S, Song R, Kamya P, Bruneau J, Shoukry NH, et al. 2010. HIV protective KIR3DL1 and HLAB genotypes influence NK cell function following stimulation with HLA-devoid cells. J. Immunol. 184:2057-64.
153. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, et al. 2003. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J. Immunol. 171:5663-67. (Pubitemid 37467178)
154. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, et al. 2007. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 109:4296-305. (Pubitemid 46743396)
155. Boulet S, Sharafi S, Simic N, Bruneau J, Routy JP, et al. 2008. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 22:595-99. (Pubitemid 351640592)
156. Boulet S, Kleyman M, Kim JY, Kamya P, Sharafi S, et al. 2008. A combined genotype of KIR3DL1 high expressing alleles and HLA-B-57 is associated with a reduced risk of HIV infection. AIDS 22:1487-91